胰岛移植是医治I型糖尿病的优秀办法。然而,由于捐助者数量有限,繁琐的分离和纯化程序,免疫排斥反应,临床应用受到很大限制。开发一种简单有效的获得胰岛β细胞的新方法是治疗I型糖尿病迫切需要解决方案的关键问题。
在这项研究中,Pbx1,Rfx3,Pdx1,Ngn3,Pax4和MafA用于形成六基因组合,以有效地将aMSCs(脂肪间充质干细胞)重编程为ra-βCs(重编程aMSCs来源的胰岛β细胞),并检测了ra-βCs的特性和免疫原性。检测了ra-βCs移植治疗模型犬和临床犬糖尿病的可行性。
在这项研究中,使用六基因组合将MSC有效地重新编程为ra-βCs。ra-βCs表现出胰岛β细胞特征。检测到ra-βCs的免疫原性,并在体外保持较低,并在移植后增加。RA-βCs与aMSCs联合移植治疗犬糖尿病模型及临床病例取得了理想的治疗效果。
使用六基因组合将aMSC有效地重编程为ra-βCs。RA-βCs和aMSCs联合移植治疗犬糖尿病是可行的,为犬糖尿病的治疗提供了理论依据和治疗方法。
Islet transplantation is an excellent method for the treatment of type I diabetes mellitus. However, due to the limited number of donors, cumbersome isolation and purification procedures, and immune rejection, the clinical application is greatly limited. The development of a simple and efficient new method to obtain islet β-cells is a key problem that urgently requires a solution for the treatment of type I diabetes mellitus.
In this study, Pbx1, Rfx3, Pdx1, Ngn3, Pax4 and MafA were used to form a six-gene combination to efficiently reprogram aMSCs (adipose mesenchymal stem cells) into ra-βCs (reprogrammed aMSCs-derived islet β-cells), and the characteristics and immunogenicity of ra-βCs were detected. Feasibility of ra-βCs transplantation for the treatment of diabetes mellitus in model dogs and clinical dogs was detected.
In this study, aMSCs were efficiently reprogrammed into ra-βCs using a six-gene combination. The ra-βCs showed islet β-cell characteristics. The immunogenicity of ra-βCs was detected and remained low in vitro and increased after transplantation. The cotransplantation of ra-βCs and aMSCs in the treatment of a model and clinical cases of canine diabetes mellitus achieved ideal therapeutic effects.
The aMSCs were efficiently reprogrammed into ra-βCs using a six-gene combination. The cotransplantation of ra-βCs and aMSCs as a treatment for canine diabetes is feasible, which provides a theoretical basis and therapeutic method for the treatment of canine diabetes.